Increased Serum Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in FSGS: A Meta-Analysis

Table 2

Summary of all meta-analysis data comparing primary FSGS with healthy and disease controls.

Group comparison	No. of studies	No. of subjects		suPAR levels (pg/ml)		Meta-analysis			Heterogeneity
						Std diff in means	95% CI		(%)	Tau^2
pFSGS vs. Controls	9	pFSGS 418	Controls 396	pFSGS	Controls	1.07	0.65	1.48	85	0.31	<0.001
pFSGS vs. MCD	13	pFSGS 603	MCD 389	pFSGS	MCD	0.53	0.22	0.84	76	0.21	0.0009
pFSGS vs. MN	7	pFSGS 430	MGN 236	pFSGS	MN	0.36	-0.01	0.73	75	0.17	0.0005
pFSGS vs. IgAN	3	pFSGS 153	IgAN 46	pFSGS	IgAN	0.29	-0.30	0.88	52	0.14	0.33
pFSGS-A vs. FSGS-R	2	pFSGS-A 90	pFSGS-R 62	pFSGS-A	pFSGS-R	0.16	-0.63	0.95	75	0.25	0.05

Abbreviations used: SUPAR: soluble urokinase-type plasminogen activator receptor; pFSGS: primary focal segmental glomerulosclerosis; pFSGS-A: active primary FSGS in remission; pFSGS-R: pFSGS in remission; MCD: minimal change disease; MN: membranous nephropathy; IgAN: immunoglobulin A nephropathy. values were all two-tailed. Hedges’ , random effect.